Bolt Biotherapeutics Inc
NASDAQ:BOLT

Watchlist Manager
Bolt Biotherapeutics Inc Logo
Bolt Biotherapeutics Inc
NASDAQ:BOLT
Watchlist
Price: 5.6 USD 8.53% Market Closed
Market Cap: 10.8m USD

Operating Margin
Bolt Biotherapeutics Inc

-860.8%
Current
-1 147%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-860.8%
=
Operating Profit
-44.7m
/
Revenue
5.2m

Operating Margin Across Competitors

No Stocks Found

Bolt Biotherapeutics Inc
Glance View

Market Cap
10.7m USD
Industry
Biotechnology

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company is headquartered in Redwood City, California and currently employs 91 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The Company’s products include BDC-1001, BDC-2034, BDC-3042 and PD-L1 Boltbody Immune-Stimulating Antibody Conjugate (ISAC). The Company’s lead product candidate, BDC-1001, is in clinical development for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. BDC-2034 is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). CEA is a well-known tumor antigen expressed in various solid tumors with significant unmet medical need. BDC-3042 is an agonist antibody targeting Dectin-2, which is an innate immune receptor found on the surface of macrophages. PD-L1 Boltbody ISAC focused on the treatment of patients with tumors that are nonresponsive or become refractory to immune checkpoint blockade.

BOLT Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-860.8%
=
Operating Profit
-44.7m
/
Revenue
5.2m
What is the Operating Margin of Bolt Biotherapeutics Inc?

Based on Bolt Biotherapeutics Inc's most recent financial statements, the company has Operating Margin of -860.8%.

Back to Top